Publications by authors named "Mayte Sanchez Van Kammen"
Article Synopsis
- A significant portion of patients (1 in 10) experience epilepsy after having cerebral venous thrombosis (CVT), but it's challenging to predict who will be affected.* -
- Researchers created the DIAS3 prognostic score using clinical data from over 1,100 patients to assess the likelihood of developing post-CVT epilepsy based on six clinical variables.* -
- The study found a range of predicted risks for post-CVT epilepsy within one and three years, with successful validation of the score confirming its effectiveness in estimating individual risk.*
Article Synopsis
- The article has a Digital Object Identifier (DOI) that allows it to be easily found online.
- The DOI number given is 10.3389/fneur.2023.1251581.
- This correction is important for making sure the information in the article is accurate.
Article Synopsis
- The study aimed to validate the SINCALC score, which predicts poor outcomes and mortality in patients with cerebral venous thrombosis (CVT), using an international cohort from the ACTION-CVT study.
- The ACTION-CVT cohort showed differences from the original International CVT Consortium, being older, having fewer females, and milder symptoms, with a mortality rate of 2.5% at 30 days and 6% at one year.
- Results indicated the SINCALC score performed reasonably well in predicting outcomes, with AUC values suggesting its effectiveness, and further validation in diverse populations is recommended.
Introduction: Previous reports and meta-analyses derived from small case series reported a mortality rate of up to 40% in patients with coronavirus disease 2019 associated cerebral venous thrombosis (COVID-CVT). We assessed the clinical characteristics and outcomes in an international cohort of patients with COVID-CVT.
Patients And Methods: This was a registry study of consecutive COVID-CVT patients diagnosed between March 2020 and March 2023.
Background: Decompressive neurosurgery is recommended for patients with cerebral venous thrombosis (CVT) who have large parenchymal lesions and impending brain herniation. This recommendation is based on limited evidence. We report long-term outcomes of patients with CVT treated by decompressive neurosurgery in an international cohort.
View Article and Find Full Text PDFArticle Synopsis
- The text outlines the challenges of conducting research on cerebral venous thrombosis (CVT) due to its rarity, emphasizing the need for a prioritized international research agenda to enhance prevention, diagnosis, and treatment for better patient outcomes.
- The agenda was developed during a summit in June 2023, involving 45 participants from 15 countries, including clinical researchers, former CVT patients, and representatives from funding organizations, focused on key research themes.
- It categorizes essential research questions into themes like epidemiology, diagnosis, medical treatment, and more, aiming to inspire future research, foster collaboration, and help secure funding to address these critical questions in CVT.
Article Synopsis
- Current guidelines suggest treating cerebral venous thrombosis (CVT) with vitamin K antagonists (VKAs) for 3-12 months, but direct oral anticoagulants (DOACs) like dabigatran are becoming popular due to promising results in smaller studies.
- The DOAC-CVT study is an international, observational trial aiming to compare the effectiveness and safety of DOACs and VKAs in preventing recurrent blood clots after CVT, involving at least 500 patients over three years.
- The study's primary goal is to evaluate the rates of recurrent venous thrombotic events and major bleeding within six months, providing real-world insights into treatment options for CVT.
Introduction: There is little data on the role of endovascular treatment (EVT) of cerebral venous sinus thrombosis (CVST) due to vaccine-induced immune thrombotic thrombocytopenia (VITT). Here, we describe clinical characteristics and outcomes of CVST-VITT patients who were treated with EVT.
Patients And Methods: We report data from an international registry of patients who developed CVST within 28 days of SARS-CoV-2 vaccination, reported between 29 March 2021 and 6 March 2023.
Article Synopsis
- A study investigated sex differences in cerebral venous sinus thrombosis associated with vaccine-induced immune thrombotic thrombocytopenia (CVST-VITT), revealing that 77% of the patients were women.
- Women presented with more severe symptoms, such as coma and lower platelet counts, and more women underwent endovascular treatment compared to men.
- Despite these differences in presentation and treatment, the overall clinical outcomes, including complications and in-hospital mortality, were similar for both sexes.
Article Synopsis
- Adenovirus-based COVID-19 vaccines are widely used in low- and middle-income countries (LMICs), but cases of vaccine-induced cerebral venous sinus thrombosis (CVST) are rarely reported.
- A study of 228 CVST cases showed 63 from LMICs, with 51% meeting vaccine-induced immune thrombotic thrombocytopenia (VITT) criteria, compared to 62% from high-income countries (HICs).
- Although clinical manifestations were similar, in-hospital mortality was significantly lower in LMICs (23%) compared to HICs (43%), suggesting different outcomes despite similar treatment approaches.
Article Synopsis
- A new prognostic score, SI NCAL C, was created to estimate the risk of dependency and death in patients after cerebral venous thrombosis (CVT), aiding in future targeted therapies.
- The study used data from the International CVT Consortium, excluding patients with prior functional dependency, and employed logistic and Cox regression analyses to identify risk factors for poor outcomes.
- Results showed the score has good predictive accuracy (C-statistics around 0.80-0.84), but further external validation is needed to confirm its effectiveness before widespread use.
Article Synopsis
- Cerebral venous sinus thrombosis due to vaccine-induced immune thrombotic thrombocytopenia (CVST-VITT) can lead to severe bleeding and high mortality, particularly among patients requiring decompressive surgery post-COVID vaccination.
- A study reviewed 128 CVST-VITT patients, finding that 27% underwent surgery, with a 65% in-hospital mortality rate in this group compared to 29% in non-surgical patients, highlighting factors like preoperative coma and pupillary reflex absence as key mortality predictors.
- Despite the high mortality, around 80% of the surgical survivors were functionally independent at a 6-month follow-up, indicating some potential for recovery even after critical interventions.
Article Synopsis
- Cerebral venous thrombosis (CVT) associated with vaccine-induced immune thrombotic thrombocytopenia (VITT) has high in-hospital mortality, but outcomes are better for those who survive hospitalization after SARS-CoV-2 vaccination.
- In a study of 107 CVT-VITT cases, 40% died during initial hospitalization, but of the 60 patients who survived, 88% achieved functional independence after a median follow-up of 150 days.
- No new thrombotic events were reported post-discharge, and only one case of major bleeding occurred, indicating a generally positive prognosis for survivors.
Article Synopsis
- The relationship between stroke and cancer is increasingly significant, especially as the population ages and cancer survival rates improve, leading to more cases of patients experiencing both conditions simultaneously.
- Patients with concurrent cancer often show higher markers of clotting and have different stroke characteristics, such as more frequent multiple infarctions and denser clots compared to those without cancer.
- Clinicians can utilize new MRI techniques and a cancer probability score during stroke evaluations to guide cancer screenings, while treatment decisions, particularly for thrombolysis and thrombectomy, must be carefully considered based on the cancer's stage and patient's overall health.
Article Synopsis
- The study investigates the treatment of cerebral venous thrombosis (CVT) caused by vaccine-induced immune thrombotic thrombocytopenia (VITT) following adenovirus-based COVID-19 vaccinations.
- Researchers analyzed data from 99 patients across 17 countries to assess adherence to recommended treatments, including immunomodulation and avoiding certain anticoagulants.
- While overall adherence to these treatment guidelines did not significantly impact mortality, patients who received immunomodulation showed lower mortality rates compared to those who did not.
Background: Cerebral venous thrombosis (CVT) has recently been reported as a common thrombotic manifestation in association with vaccine-induced thrombotic thrombocytopenia, a syndrome that mimics heparin-induced thrombocytopenia (HIT) and occurs after vaccination with adenovirus-based SARS-CoV-2 vaccines. We aimed to systematically review the incidence, clinical features, and prognosis of CVT occurring in patients with HIT.
Methods: The study protocol was registered with PROSPERO (CRD42021249652).
Background: We aimed to describe the clinical presentation, risk of bleeding and recurrent thrombosis, and perioperative anticoagulant management of children with cerebral venous thrombosis (CVT) and an associated head or neck infection.
Methods: In this subgroup analysis of the EINSTEIN-Jr study, we included children with CVT and an associated head or neck infection who received therapeutic anticoagulants with either low-molecular-weight heparin (with or without subsequent vitamin K antagonists) or rivaroxaban for a period of 3 months. Analyses are descriptive.
Background And Objectives: Cerebral venous sinus thrombosis (CVST) as a part of the thrombosis and thrombocytopenia syndrome is a rare adverse drug reaction of severe acute respiratory syndrome coronavirus disease 2 (SARS-CoV-2) vaccination. Estimated background rate of CVST with thrombocytopenia is 0.1 per million per month.
View Article and Find Full Text PDFDural arteriovenous fistulas in cerebral venous thrombosis: Data from the International Cerebral Venous Thrombosis Consortium: Data from the International Cerebral Venous Thrombosis Consortium.
Eur J Neurol
March 2022
Article Synopsis
- The study investigates the prevalence and characteristics of dural arteriovenous fistulas (dAVFs) in patients with cerebral venous thrombosis (CVT), finding that 2.4% of CVT patients had dAVFs.
- It highlights that patients with dAVFs tend to be older, predominantly male, and more likely to experience chronic CVT onset, with specific imaging findings.
- Despite these associations, the clinical outcomes for patients with and without dAVFs were similar, with most fistulas identified either at the time of CVT diagnosis or afterward.
Article Synopsis
- - The study focuses on patients who developed cerebral venous sinus thrombosis (CVST) after receiving SARS-CoV-2 vaccines, specifically ChAdOx1 (Oxford-AstraZeneca) and Ad26.COV2.S (Johnson & Johnson), particularly looking at those with thrombosis with thrombocytopenia syndrome (TTS) versus those without.
- - Data was gathered from an international registry from 81 hospitals spanning 19 countries, highlighting the clinical characteristics and mortality rates of patients with CVST in relation to their vaccination status.
- - Of 116 postvaccination CVST patients, 67.2% had TTS, predominantly after the ChAdOx1 vaccine, with a notable percentage of female patients and
Article Synopsis
- High mortality rates have been seen in patients with cerebral venous sinus thrombosis (CVST) caused by vaccine-induced immune thrombotic thrombocytopenia (VITT) following adenoviral vector SARS-CoV-2 vaccinations.
- A study using the EudraVigilance database assessed cases of CVST with thrombocytopenia occurring within 28 days post-vaccination, comparing cases before and after the first scientific paper on VITT was published on March 28, 2021.
- Results showed a significant decrease in mortality rates from 47% in earlier cases to 22% in later cases for adenoviral vaccines, while no deaths occurred in CVST cases following mRNA vaccinations, highlighting improved
Background And Purpose: Cerebral venous sinus thrombosis (CVST) has been described after vaccination against SARS-CoV-2. The clinical characteristics of 213 post-vaccination CVST cases notified to the European Medicines Agency are reported.
Methods: Data on adverse drug reactions after SARS-CoV-2 vaccination notified until 8 April 2021 under the Medical Dictionary for Regulatory Activities Term 'Central nervous system vascular disorders' were obtained from the EudraVigilance database.
Article Synopsis
- Cerebral venous sinus thrombosis cases combined with thrombocytopenia have emerged after vaccinations with the AstraZeneca and Johnson & Johnson COVID-19 vaccines, linked to an immune response involving platelet factor 4/heparin antibodies.
- The study aims to evaluate how often patients diagnosed with cerebral venous sinus thrombosis before the pandemic experienced thrombocytopenia and had the associated antibodies.
- Out of 865 patients analyzed, about 8.4% presented with thrombocytopenia, with varying severity levels (mild to moderate).
Anticoagulant treatment of pediatric cerebral venous thrombosis has not been evaluated in randomized trials. We evaluated the safety and efficacy of rivaroxaban and standard anticoagulants in the predefined subgroup of children with cerebral venous thrombosis (CVT) who participated in the EINSTEIN-Jr trial. Children with CVT were randomized (2:1), after initial heparinization, to treatment with rivaroxaban or standard anticoagulants (continued on heparin or switched to vitamin K antagonist).
View Article and Find Full Text PDF